Literature DB >> 19124125

High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study.

C Schmidt1, J Wikstrand.   

Abstract

OBJECTIVES: The aim of the present study was to investigate the relationship between atherosclerotic progression rate as measured by carotid artery IMT during very long-term follow-up in clinically healthy men and a number of baseline risk factors of potential importance for atherosclerosis progression including apoA-I, apoB, apoB/apoA-I ratio, other lipid variables including LDL particle size, body composition variables, blood pressure, smoking, fasting blood glucose and insulin, and also hsCRP.
BACKGROUND: Low-density lipoprotein (LDL) is associated with increased carotid IMT progression rate during long-term follow-up, whereas the relationship between newer biomarkers such as apoB/apoA-I ratio and carotid artery IMT progression rate has been less investigated.
METHODS: 58-year-old men identified by screening in the community (n=391) with varying degrees of obesity and insulin sensitivity were examined with high-resolution B-mode ultrasound at baseline and after 3, and 8.9 years of follow-up (n=305 investigated after 8.9 years). The carotid arteries were examined bilaterally, and the mean intima-thickness was calculated for 10mm sections of the composite of common carotid arteries and bulbs (IMT(composite)). Serum levels of apoB and apoA-I were measured using a turbidimetric method. Uni- and multi-variable analyses were performed to study the relationship between carotid IMT(composite) progression rate and risk factors.
RESULTS: In a multi-variable analysis including all baseline variables only the apoB/apoA-I ratio (p=0.003; beta=0.181, standard error=0.003) and serum insulin (p=0.026; beta=-0.133, standard error=0.000) was significantly related to IMT(composite) progression rate.
CONCLUSION: The results indicate that apoB/apoA-I ratio is an important risk factor for predicting atherosclerotic progression rate during very long-term follow-up in clinically healthy middle-aged men.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19124125     DOI: 10.1016/j.atherosclerosis.2008.11.025

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Hong Fang; Ehtisham Akhter; Carmen Quiroga; Nancy Simpson; Petar Alaupovic; Laurence S Magder; Michelle Petri
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-03       Impact factor: 4.794

2.  Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants.

Authors:  Brian T Steffen; Weihua Guan; Alan T Remaley; James H Stein; Mathew C Tattersall; Joel Kaufman; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2017-07-12       Impact factor: 4.766

3.  Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects.

Authors:  Anders Gummesson; Ulf Strömberg; Caroline Schmidt; Joel Kullberg; Oskar Angerås; Stefan Lindgren; Ola Hjelmgren; Kjell Torén; Annika Rosengren; Björn Fagerberg; John Brandberg; Göran Bergström
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

4.  Symptomatic atherosclerosis is associated with an altered gut metagenome.

Authors:  Fredrik H Karlsson; Frida Fåk; Intawat Nookaew; Valentina Tremaroli; Björn Fagerberg; Dina Petranovic; Fredrik Bäckhed; Jens Nielsen
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

5.  Comparison of Apolipoprotein Concentrations and Values of APOB:APOAI with Traditional Lipid Measures in Women Diagnosed with Acute Cornonary Syndromes - A Preliminary Report.

Authors:  Magdalena Krintus; Katarzyna Bergmann; Grazyna Sypniewska; Marcin Sawicki
Journal:  EJIFCC       Date:  2011-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.